207 related articles for article (PubMed ID: 6202970)
1. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs.
Tanabe M; Terashita Z; Nishikawa K; Hirata M
J Cardiovasc Pharmacol; 1984; 6(3):442-8. PubMed ID: 6202970
[TBL] [Abstract][Full Text] [Related]
2. Coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion in anaesthetised dogs.
Tanabe M; Terashita ZI; Fujiwara S; Shimamoto N; Goto N; Nishikawa K; Hirata M
Cardiovasc Res; 1982 Feb; 16(2):99-106. PubMed ID: 7074670
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs.
Imamoto T; Terashita Z; Tanabe M; Nishikawa K; Hirata M
J Cardiovasc Pharmacol; 1986; 8(4):832-9. PubMed ID: 2427826
[TBL] [Abstract][Full Text] [Related]
4. Lack of thromboxane A2 involvement in the arrhythmias occurring during acute myocardial ischemia in dogs.
Burke SE; Antonaccio MJ; Lefer AM
Basic Res Cardiol; 1982; 77(4):411-22. PubMed ID: 6890805
[TBL] [Abstract][Full Text] [Related]
5. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart.
Sakai K; Ito K; Ogawa K
J Cardiovasc Pharmacol; 1982; 4(1):129-35. PubMed ID: 6176788
[TBL] [Abstract][Full Text] [Related]
6. Effect of 2-phenylaminoadenosine (CV-1808) on ischemic ST-segment elevation in anesthetized dogs.
Matsumoto N; Kawazoe K; Tanabe M; Imamoto T; Fujiwara S; Hirata M
J Cardiovasc Pharmacol; 1981; 3(6):1184-92. PubMed ID: 6173517
[TBL] [Abstract][Full Text] [Related]
7. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
[TBL] [Abstract][Full Text] [Related]
8. Platelet thromboxane production during endotoxin shock.
Prancan A; Simon D; Pope L
Agents Actions; 1981 Dec; 11(6-7):648-50. PubMed ID: 7340458
[TBL] [Abstract][Full Text] [Related]
9. Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model.
Toki Y; Hieda N; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
Arzneimittelforschung; 1988 Feb; 38(2):224-7. PubMed ID: 3370068
[TBL] [Abstract][Full Text] [Related]
10. Delay of the initiation of hypertension in spontaneously hypertensive rats by CV-4151, a specific thromboxane A2 synthetase inhibitor.
Shibouta Y; Terashita Z; Inada Y; Nishikawa K
Eur J Pharmacol; 1985 Feb; 109(2):135-44. PubMed ID: 3922775
[TBL] [Abstract][Full Text] [Related]
11. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
Vandeplassche G; Hermans C; Van Dael L; Wouters L; De Clerck F
J Cardiovasc Pharmacol; 1993 Jan; 21(1):56-69. PubMed ID: 7678680
[TBL] [Abstract][Full Text] [Related]
12. Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: evidence for alternate pathways for coronary thrombosis.
Hook BG; Schumacher WA; Lee DL; Jolly SR; Lucchesi BR
J Cardiovasc Pharmacol; 1985; 7(1):174-81. PubMed ID: 2580139
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
Ashton JH; Schmitz JM; Campbell WB; Ogletree ML; Raheja S; Taylor AL; Fitzgerald C; Buja LM; Willerson JT
Circ Res; 1986 Nov; 59(5):568-78. PubMed ID: 3542279
[TBL] [Abstract][Full Text] [Related]
14. Redirection of arachidonic acid metabolism by ICI D1542: effects on thrombus formation in the coronary artery of the anaesthetized dog.
McAuliffe SJ; Moors JA; Snow HM; Wayne M; Jessup R
Br J Pharmacol; 1993 Apr; 108(4):901-6. PubMed ID: 8485629
[TBL] [Abstract][Full Text] [Related]
15. RCS from human platelets: is it only thromboxane?
Smith EF; Rücker W; Schrör K
Eur J Pharmacol; 1983 Nov; 95(1-2):121-4. PubMed ID: 6667711
[TBL] [Abstract][Full Text] [Related]
16. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
de Chaffoy de Courcelles D; De Clerck F
Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
[TBL] [Abstract][Full Text] [Related]
17. The anti-thromboxane A2 synthetase activity of myocardial tissue and its variation during ischemia and reperfusion in isolated rabbit heart.
Chahine R; Lasserre B; Assaad S
Prostaglandins Leukot Essent Fatty Acids; 1999 Feb; 60(2):101-6. PubMed ID: 10328329
[TBL] [Abstract][Full Text] [Related]
18. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
Grover GJ; Schumacher WA; Simon M; Parham C
J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
[TBL] [Abstract][Full Text] [Related]
19. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
[TBL] [Abstract][Full Text] [Related]
20. Arachidonate metabolism in myocardial ischemia and reperfusion.
Tada M; Kuzuya T; Hoshida S; Nishida M
J Mol Cell Cardiol; 1988 Mar; 20 Suppl 2():135-43. PubMed ID: 3137347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
